Learning Center for the MDS Foundation
2020 ASH Registration

Virtual Symposium
December 4, 2020
7:00 am – 10:00 am PST

Register Now

**Please note that CME credits will only be available to participants that attend the live symposium.

ACTIVITY OVERVIEW
Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).

AGENDA TOPICS

  • Challenges in MDS diagnosis
  • Managing MDS in the wake of a global pandemic
  • Venetoclax in higher-risk MDS/AML
  • Role of CAR-T cells in myeloid malignancies: lessons learned from lymphoid malignancies
  • Targeted therapies (enasidenib, ivosidenib, APR-246)

LEARNING OBJECTIVES

  • Describe molecular profiling in diagnostic and prognostic evaluation of MDS.
  • Evaluate the impact of COVID-19 on management of MDS patients
  • Utilize venetoclax in higher-risk MDS patients
  • Identify the prospects of adoptive cellular immunotherapy modalities and novel transplant-related approaches in MDS
  • Describe targeted therapies in MDS.

FACULTY

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Fondazione IRCCS Policlinico S. Matteo
University of Pavia
Pavia, Italy

Jane Churpek, MD – Symposium Co-Chair

Assistant Professor, Division of Hematology, Oncology, and Palliative Care
Department of Medicine
The University of Wisconsin School of Medicine and Public Health &
The University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, USA

Stephen Nimer, MD – MDSF Chairman

St. James’s University Hospital
Haematological Malignancy Diagnostic Service
Leeds, United Kingdom

Rafael Bejar, MD, PhD

Associate Professor
University of California, San Diego
Moores Cancer Center
La Jolla, California, USA

Amy DeZern, MD, MHS

Associate Professor of Oncology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, USA

Katharina S. Götze, MD

Technische Universität Müchen
Department of Medicine III
Munich, Germany

Saar Gill, MD, PhD

Assistant Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania
Philadelphia, PA, USA

Stéphane de Botton, Md, PhD

Head Multidisciplinary Committee
Hematology Department
Gustave Roussy
Villejuif Cedex, France

AGENDA

Co-Chairs: Mario Cazzola, MD (Pavia, Italy),  Jane Churpek, MD (Madison, Wisconsin, USA)

7:00 – 7:05 am Welcome – About the MDS Foundation, Inc
Stephen Nimer, MD (MDSF Chairman)
Miami, Florida, USA
7:05 – 7:15 am Program Overview and Objectives
Mario Cazzola, MD
Pavia, Italy
7:15 – 7:45 am Challenges in MDS Diagnosis
Rafael Bejar, MD, PhD
San Diego, California, USA
7:45 – 8:15 am Managing MDS in the Wake of a Global Pandemic
Amy DeZern, MD
Baltimore, Maryland, USA
8:15 – 8:45 am Venetoclax in Higher-Risk MDS/AML
Katharina S. Götze, MD
Munich, Germany
8:45 – 9:15 am Role of CAR-T Cells in Myeloid Malignancies: Lessons Learned from Lymphoid Malignancies
Saar Gill, MD, PhD
Philadelphia, Pennsylvania, USA
9:15 – 9:45 am Targeted Therapies (enasidenib, ivosidenib, APR-246)
Stéphane de Botton, MD, PhD
Villejuif Cedex, France
9:45 – 10:00 am Conclusions & Perspectives
Jane Churpek, MD

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://www.mds-foundation.org/learning-center/2020-ash-registration/ You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

ACCREDITATION

AKH LOGO
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

PHYSICIANS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

PHARMACY

ACPE LOGO

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge- based activity for 2.75 contact hour(s) (0.275 CEUs). UAN 0077-9999-20-015-L04-P.

NURSING

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is awarded 2.75 Contact Hours.

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).

COMMERCIAL SUPPORT
This activity is supported by educational grants from AbbVie Inc., Astex Pharmaceuticals, Inc., Bristol-Myers Squibb, Daiichi Sankyo, Inc., Gamida Cell Ltd. Cell Therapy Technologies and Onconova Therapeutics, Inc.

AMERICANS WITH DISABILITIES ACT

AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act.  If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.

*Activity and faculty subject to change

**Please note that CME credits will only be available to participants that attend the live symposium.

Register Now

Message Board
Review answers to commonly asked questions or get answers to your questions from an MDS expert